New insights into the burden and costs of multiple sclerosis in Europe

Gisela Kobelt, Alan J. Thompson, Jenny Berg, Mia Gannedahl, Jennifer Eriksson

Multiple Sclerosis Journal · 2017 · 729 citations · 18 references

DOIFull text

Open access

Concepts

TL;DR

The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention, with a view to modifying disease progression, and healthcare costs have shifted from inpatient care and rehabilitation to outpatient care; this European burden of illness study provides data that can be combined with other evidence to assess whether management approaches provide value to society, based on a cross‑sectional study in 16 countries. The study aims to provide data that can be combined with other evidence to assess whether management approaches for multiple sclerosis provide value to society, using a cross‑sectional design across 16 European countries. The authors collected patient‑reported disease status, HRQoL, and resource consumption data from 16,808 participants across 16 countries and performed descriptive analyses by disease severity, reporting costs from a societal perspective in 2015€ PPP. Work capacity and utility decline sharply with disease severity, with mean societal costs rising from 22,800€ PPP in mild to 57,500€ PPP in severe MS, while fatigue and cognitive difficulties affect utility, and costs and utility correlate strongly with severity but are also shaped by healthcare system organization.

Abstract

The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention, with a view to modifying disease progression. Consequently, healthcare costs have shifted from inpatient care and rehabilitation to outpatient care.This European burden of illness study provides data that can be combined with other evidence to assess whether management approaches provide value to society.A cross-sectional study was conducted in 16 countries. Patients reported on their disease, health-related quality of life (HRQoL) and resource consumption. Descriptive analyses were performed by disease severity. Costs are reported from a societal perspective in 2015€ PPP (adjusted for purchasing power parity).The 16,808 participants had a mean age of 51.5 years, and 52% had relapsing-remitting multiple sclerosis (RRMS). Work capacity declined from 82% to 8%, and utility declined from normal population values to less than zero with advancing disease. Mean costs were 22,800€ PPP in mild, 37,100€ PPP in moderate and 57,500€ PPP in severe disease; healthcare accounted for 68%, 47% and 26%, respectively. Fatigue and cognitive difficulties were reported by 95% and 71% of participants, respectively; both had a significant independent effect on utility.Costs and utility were highly correlated with disease severity, but resource consumption was heavily influenced by healthcare systems organisation and availability of services.

References

18